BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
Biohaven Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$11.35+0.57 (+5.29%)
Close on Oct 19, 2026
- Market cap
- $1.71B
- P/E (TTM)
- –
- Dividend yield
- –
Biohaven Ltd. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -310.8%
Financial strength
- Current ratio
- 4.73
- Debt to equity
- 21.23
- Debt to assets
- 70.0%
- Cash to current liabilities
- 379.9%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 139.89
- Dividend yield
- –